U.S. markets closed

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.96+1.01 (+14.53%)
At close: 4:00PM EDT

Paratek Pharmaceuticals, Inc.

75 Park Plaza
4th Floor
Boston, MA 02116
United States
617 807 6600
http://paratekpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees196

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. Bigham CPA, M.B.A., CPA, MBAExec. Chairman881.68kN/A1958
Dr. Evan LohCEO & Director906.9kN/A1959
Mr. Adam WoodrowPres & Chief Commercial Officer672.21kN/A1967
Mr. William M. HaskelSr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer586kN/A1962
Ms. Sarah HigginsVP, Controller and Interim Principal Financial & Accounting OfficerN/AN/A1975
Mr. Jason BurdetteSr. VP of Technical OperationsN/AN/AN/A
Mr. Ben StrainVP of Investor Relations & Corp. Communications and Chief of Staff to the CEON/AN/AN/A
Ms. Christine R. Coyne M.B.A.VP of MarketingN/AN/AN/A
Ms. Karen McGrathSr. VP of HRN/AN/AN/A
Mr. Randall B. BrennerChief Devel. & Regulatory OfficerN/AN/A1973
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Corporate Governance

Paratek Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 10. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.